Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Cash from Financing Activities (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Cash from Financing Activities for 10 consecutive years, with $265359.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Cash from Financing Activities rose 5.92% year-over-year to $265359.0, compared with a TTM value of $265359.0 through Sep 2025, down 98.23%, and an annual FY2024 reading of $15.5 million, up 159.77% over the prior year.
  • Cash from Financing Activities was $265359.0 for Q2 2025 at Kiora Pharmaceuticals, up from $250523.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $15.2 million in Q1 2024 and bottomed at -$486421.0 in Q4 2023.
  • Average Cash from Financing Activities over 4 years is $4.4 million, with a median of $513175.0 recorded in 2023.
  • The sharpest move saw Cash from Financing Activities plummeted 197.38% in 2021, then surged 2871.23% in 2024.
  • Year by year, Cash from Financing Activities stood at -$212282.0 in 2021, then plummeted by 129.14% to -$486421.0 in 2023, then soared by 151.5% to $250523.0 in 2024, then rose by 5.92% to $265359.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for KPRX at $265359.0 in Q2 2025, $250523.0 in Q2 2024, and $15.2 million in Q1 2024.